HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

AMPH

Amphastar Pharmaceuticals, Inc. (NASDAQ)

Healthcare — Drug Manufacturers - Specialty & Generic

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Hold 3.1 / 5 6 analysts
$19.37
$-0.22 (-1.12%)
Target: $22.00 (13.6%)
Sign in to add AMPH to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$889.80M
P/E Ratio (TTM)12.16
Forward P/E6.64
EPS (TTM)$1.66
Dividend Yield-
Profit Margin11.00%
Revenue Growth0.40%
ROE10.39%
Debt/Equity88.75
Recommendation Hold 3.1
Analyst Target$22.00
Analysts6
Indexes NASDAQ

Technical Indicators

RSI (14)50.1
Beta0.90
SMA 20-
SMA 40-
52-Week High$31.26
52-Week Low$16.65
50-Day Avg$20.02
200-Day Avg$23.77
Avg Volume608.7K
Volume255.6K

Performance Analysis

NEUTRAL

AMPH presents a mixed picture with both positive and negative indicators.

~ Trading at 19% of its 52-week range.
~ RSI at 50.1 is in neutral territory.
- Price is below both the 50-day and 200-day moving averages — in a downtrend.
+ P/E of 12.2 suggests the stock may be undervalued.
~ Modest revenue growth of 0.4% year-over-year.
~ Wall Street consensus is "Hold" from 6 analysts.
+ Average analyst target of $22.00 implies 13.6% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jun 30, 2026 21:07 UTC

Back to Screener Export Report